Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight ...
Cantor Fitzgerald reaffirmed their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald ...
Pete Stavropoulos; Analyst; Cantor Fitzgerald & Co. Good afternoon and welcome to Voyager Therapeutics fourth-quarter and year-end 2024 financial results conference call. (Operator Instructions ...
Voyager Therapeutics, Inc. LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines ...
Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report), ...
Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...
LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $34.5 million in its fourth quarter. On a per-share basis, the Lexington ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback